KIT and gastrointestinal stromal tumor: Importantly, masitinib was a potent inhibitor of several gain-of-function KIT mutants, including V559D (exon 11), which is associated with GIST [6], and a murine KIT mutant with a deletion of nine amino acids in the juxtamembrane domain (Δ27 mutant; exon 11).